A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
Trial Number
NCT05173987 (ClinicalTrials.gov Identifier)Contact Person
Status
Recruiting
Disease Site
Endometrial
Lead Cooperative Group
Participating Groups
BGOG
CEEGOG
NSGO-CTU
NOGGO
ISGO
MaNGO
DGOG
CTI
GEICO
NCRI